jueves, 17 de diciembre de 2015

Cervical Cancer Screening—Health Professional Version - National Cancer Institute

Cervical Cancer Screening—Health Professional Version - National Cancer Institute

National Cancer Institute

Cervical Cancer Screening–for health professionals (PDQ®)


Changes to This Summary (12/10/2015)

Revised text to state that this population was essentially screen naive at entry into the study and demonstrated a much higher overall risk for cervical cancer death than that observed in the U.S. population; therefore, these findings are not applicable to the United States and similar Western health care.
Added text about a demonstration project in Kolkata, India, that enrolled 39,740 women aged 30 to 60 years who underwent screening with visual inspection of the cervix with acetic acid (VIA) and Hybrid Capture II human papillomavirus (HPV) DNA testing, with colposcopy referral for a positive test followed by biopsy and treatment if indicated; estimated text performance for detection of cervical intraepithelial neoplasia severe dysplasia (CIN 3+), corrected for verification bias, demonstrated that VIA achieved a sensitivity of 59.9% and a specificity of 93.2% compared with HPV testing, which resulted in a sensitivity of 91.2% and a specificity of 96.9% (cited Basu et al. as reference 73).
This summary is written and maintained by the PDQ Screening and Prevention Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

No hay comentarios:

Publicar un comentario